martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 5, 2025

Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy?

View original at finance.yahoo.com
Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy? Shares of Bank of America BAC, the second-largest U.S. bank, are poised for another year of double-digit gains, building on its strong 30.5% rally in 2024…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bank of America projects a 5-7% year-over-year increase in NII for 2026, after similar growth this year

    80% confidence

  • Zacks Consensus Estimate for 2025 earnings per share is $3.80

    80% confidence

  • Citigroup expects NII (excluding Markets) to grow 5.5% for 2025

    80% confidence

  • Bank of America aims to achieve earnings growth of almost 12% in the medium term

    80% confidence

  • Bank of America targets mid-single-digit CAGR in IB fees and a 50 to 100-bp market share gain over the medium term

    80% confidence

  • Zacks Consensus Estimate for 2026 earnings per share is $4.35

    80% confidence

  • JPMorgan anticipates 2025 NII to be $95.8 billion, up more than 3% year over year

    80% confidence

  • Bank of America carries a Zacks Rank #2 (Buy)

    80% confidence

  • Bank of America targets a 55-59% efficiency ratio

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Bank of America Shares Climb 23.1% YTD: Is It Too Late to Buy? — Source | Via News | es.VIA.NEWS